| Literature DB >> 22760782 |
Lorena Di Lisio1, Nerea Martinez, Santiago Montes-Moreno, Miguel Piris-Villaespesa, Margarita Sanchez-Beato, Miguel A Piris.
Abstract
There is a demand to understand B-cell lymphoma pathogenesis better, to identify new markers, and to define multiple lymphoproliferative disorders more accurately. MicroRNAs (miRNAs) are regulators of protein translation, comprising a group of more than 1500 short noncoding single-strand RNA molecules of approximately 22 nucleotides in length. They are easily detectable in fresh or paraffin-embedded diagnostic tissue and serum. Expression of individual miRNAs and miRNA signatures allows specific cell-differentiation stages to be identified, and is a powerful diagnostic and prognostic method. Here we review what is known about the pathogenic relevance of miRNAs, and use of miRNAs for the diagnosis and prognosis of B-cell lymphomas. Most of the published data concern chronic lymphocytic lymphoma and diffuse large B-cell lymphoma, and implicate miRNAs in the pathogenesis of these diseases. They identify miRNAs that could be used for diagnosis, prognosis, or prediction of response to specific therapies.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22760782 DOI: 10.1182/blood-2012-05-402784
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113